The Evolution and Future of Targeted Protein Degradation Chemistry

Once a fringe idea in chemical biology, targeted protein degradation (TPD) has become one of the most watched strategies in drug discovery. TPD has created new therapeutic opportunities for previously undruggable protein targets. Leading experts will discuss the design, challenges, and clinical promise of PROTACs in overcoming limitations of traditional small molecules.

Ever wonder:

How have PROTACS, molecular glues, and linker chemistries and their related research and development evolved over the past 20 years?

How we decide on the right modality and MoA?

Which discovery technologies are available to us?

How do they translate from animals to humans?

How are companies and academic groups approaching safety assessment for degraders, particularly with respect to off‑target effects, tissue specificity, and long‑term protein knockdown?

Join us to get some answers directly from field experts.